Trivium Point Advisory’s Enzo Biochem, Inc. ENZ Stock Holding History

Trivium Point Advisory’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-19,500	Closed	-$7.21K	–	364
2025 Q1	$7.21K	Hold	19,500	–	–	﹤0.01%	336
2024 Q4	$13.9K	Hold	19,500	–	–	﹤0.01%	337
2024 Q3	$22.2K	Buy	+19,500	New	+$21.8K	﹤0.01%	325
2024 Q2	–	Sell	-19,500	Closed	-$24.8K	–	310
2024 Q1	$24.8K	Hold	19,500	–	–	0.01%	212
2023 Q4	$27.1K	Hold	19,500	–	–	0.01%	194
2023 Q3	$26.3K	Hold	19,500	–	–	0.01%	184
2023 Q2	$35.9K	Hold	19,500	–	–	0.01%	189
2023 Q1	$47.4K	Buy	19,500 +1,000	+5%	+$1.49K	0.01%	179
2022 Q4	$25.9K	Buy	18,500 +500	+3%	+$974	0.01%	181
2022 Q3	$41K	Hold	18,000	–	–	0.01%	180
2022 Q2	$39K	Hold	18,000	–	–	0.01%	193
2022 Q1	$53K	Hold	18,000	–	–	0.01%	220
2021 Q4	$58K	Hold	18,000	–	–	0.01%	239
2021 Q3	$70K	Hold	18,000	–	–	0.02%	218
2021 Q2	$57K	Hold	18,000	–	–	0.01%	209
2021 Q1	$62K	Hold	18,000	–	–	0.02%	188
2020 Q4	$48K	Hold	18,000	–	–	0.01%	179
2020 Q3	$38K	Buy	18,000 +400	+2%	+$950	0.01%	162
2020 Q2	$43K	Hold	17,600	–	–	0.02%	154
2020 Q1	$42K	Buy	17,600 +425	+2%	+$1.04K	0.02%	139
2019 Q4	$45K	Hold	17,175	–	–	0.02%	159
2019 Q3	$60K	Hold	17,175	–	–	0.03%	157
2019 Q2	$58K	Hold	17,175	–	–	0.03%	161
2019 Q1	$47K	Hold	17,175	–	–	0.02%	155
2018 Q4	$48K	Buy	+17,175	New	+$56.3K	0.03%	137

Other funds holding ENZ

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

KCM

Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

Trivium Point Advisory's ENZ Position: Q2 2025 in Review

Trivium Point Advisory sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 19,500 shares — an estimated $7.21K sold.

Trivium Point Advisory first reported a position in ENZ in Q4 2018 and held it in 25 quarters. The position peaked at $70K in Q3 2021. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

Trivium Point Advisory reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
Trivium Point Advisory sold 19,500 Enzo Biochem, Inc. shares in Q2 2025, an estimated $7.21K.
Trivium Point Advisory first reported a position in Enzo Biochem, Inc. in Q4 2018 and held it in 25 quarters.
Trivium Point Advisory's Enzo Biochem, Inc. position peaked at $70K in Q3 2021.
6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on Trivium Point Advisory's 13F filing for Q2 2025, filed 17 Jul 2025.